ProAgio in Combination With Gemcitabine in Patients With Metastatic Triple Negative Breast Cancer

NCT06460298 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

51

Enrollment

INDUSTRY

Sponsor class

Conditions

Triple Negative Breast Cancer

Interventions

DRUG: ProAgio Dose Levels (DL) 1,2,3,4
DRUG: ProAgio Dose Expansion

Sponsor

ProDa BioTech, LLC

Collaborators

[object Object]
[object Object]